A Breakthrough in Cardiovascular Health

We Use Technology to Reduce Inequality in Healthcare

We provide innovative and affordable healthcare solutions, which promise to level the playing field for millions worldwide

A patented adjustable, minimally invasive intervention to replace Pulmonary Artery Banding

The Problem

Cardiovascular Disease (CVD) is the leading cause of death worldwide

#1 CAUSE OF DEATH

31% of global deaths are a result of CVD

AFFORDABILITY

Low and middle income countries now experience the highest prevalence and mortality rates of CVDs

SCALE

31% of global deaths are a result of CVD

EFFECT

One person dies every 36 seconds in the US from CVD 

34 million
Our serviceable obtainable worldwide
market is 34 million.
$30 billion
The direct and indirect cost of treating our serviceable
market is $30 billion per annum.

Our Solution

Patented, safer and affordable solutions that reduce the risk of cardiovascular treatment

FIRST-OF-ITS-KIND

Adjustable, minimally invasive percutaneous intervention, to replace surgical Pulmonary Artery Banding (PAB)

APPLICATION

We can treat more than 10 cardio-vascular diseases using the HeartPoint Global Implant System (HPGS)

MINIMALLY INVASIVE

Solutions for both juvenile and adult congenital heart defect patients and congestive heart disease patients

RECOVERY

Excessive pulmonary artery blood flow is reduced and the normal function of the heart-lung system is partially or fully restored

Patented, safer and affordable solutions that de-risk cardiovascular treatment

1

ADJUSTABLE

HPGS allows adjustments of pressure up and/or down during or after the initial intervention to improve the structural flow of the heart-lung system.

2

SAFER

HPGS dramatically reduces mortality risk, complication risk, and the suffering associated with surgeries or transplants.

3

MINIMALLY-INVASIVE

HPGS dramatically reduces recovery times and potential complications during and after the procedure.

4

QUALITY-OF-LIFE

HPGS delivers improvements by 2 levels in cardiac function based upon the NYC Heart Association scale.

5

10+ INDICATIONS

HPGS continuously expands the spectrum of heart diseases it can treat.

The first and only minimally invasive adjustable structural heart system that brings affordability, accessibility, and the potential to save millions of lives in the developed and developing world

Total Available Market

Serviceable Available Market

Serviceable Obtainable Market

Visionary Founding Team

With extensive experience in business, operations, and healthcare

Seth Bogner

Chairman & CEO

USA, Israel

Hanna Ilesan, PhD

COO

Israel, Ireland

Brian Seidman

Managing Director

Ireland, USA

Mooneerah Karoo

CFO

Mauritius, Ireland

Cathal Brennan

Head of Reg. Affairs

Ireland

Noel Manicle

Head of Quality

Ireland

Yaniv Marmur

CTO

Israel

John Burke

Head of R&D

Ireland

Lia Bruselovky

Lead PM

Ireland

Medical Leadership

A team of innovators in the field of cardiovascular health

Dr. David Planer

Chief Interventional Cardiologist Hadassah Medical Center, Jerusalem

Israel

Prof. Dr. Paul R. Vogt

Chief of Cardiac Surgery Zurich University Hospital

Switzerland

Prof. Dr. Christian Jux

Head of the Department of Pediatric Cardiology, University Hospital Giessen

Germany

Dr. Gabby Elbaz-Greener

Interventional Cardiologist & Surgeon, Hadassah Medical Center, Jerusalem

Israel

Dr. Glib Iemets

Professor of Pediatric Cardiac Surgery, Director of Ukrainian Children’s Cardiac Center, Kiev

Ukraine

Dr. Robert Kelly

Consultant Cardiologist at Beacon Hospital, Dublin

Ireland

Prof. Dr. Sabine Däbritz

Specialist in Cardiac and thoracic Vascular Surgery, Hirslanden Private Hospital Group, Zurich

Switzerland

Prof. Emeritus Dr. Rolf Jenni

Senior Consultant for Zurich University Hospital, Inventor, Zurich

Switzerland

Contact Us

HeartPoint Global Inc. is a company with offices in US, Ireland and Israel. 

Get in touch

Address:

One Alhambra Plaza Coral Gables FL 33134

Phone:

+1 786 320 8038

Follow us: